Phase 2 Vibrance-1 Narcolepsy Agent Trial of ALKS 2680 Started by Alkermes.

Published Date: 16 May 2024

As a once-daily treatment for narcolepsy type 1, Alkermes starts the phase 2 Vibrance-1 trial to assess the safety and effectiveness of ALKS 2680 against placebo.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer

2.

Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib

3.

In prostate cancer survivorship, sleep disturbances are underappreciated.

4.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

5.

a cutting-edge cancer diagnostic tool.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot